| 张 璇,陈 茜,魏科祥,陈小平,白 璐.扶正解毒方联合恩度对晚期非小细胞肺癌患者肺功能、T细胞亚群和生存质量的影响[J].现代生物医学进展英文版,2021,(20):3974-3978. |
| 扶正解毒方联合恩度对晚期非小细胞肺癌患者肺功能、T细胞亚群和生存质量的影响 |
| The Dffect of Fuzheng Jiedu Formula Combined with Endu on Lung Function, T cell Subsets and Quality of Life in Patients with Advanced Non-small Cell Lung Cancer |
| Received:December 08, 2020 Revised:December 31, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.20.035 |
| 中文关键词: 扶正解毒方 恩度 晚期 非小细胞肺癌 T细胞亚群 生存质量 肺功能 |
| 英文关键词: Fuzheng Jiedu formula Endu Advanced Non-small cell lung cancer T cell subsets Quality of life Lung function |
| 基金项目:陕西省自然科学基础研究计划项目(2017JM8071) |
|
| Hits: 789 |
| Download times: 431 |
| 中文摘要: |
| 摘要 目的：探讨扶正解毒方联合恩度对晚期非小细胞肺癌（NSCLC）患者肺功能、T细胞亚群和生存质量的影响。方法：选取我院于2016年3月到2018年10月期间收治的晚期NSCLC患者116例，根据随机数字法将患者分为对照组（n=58，恩度联合化疗）和研究组（n=58，对照组基础上联合扶正解毒方治疗），均以21 d为一个治疗周期，共治疗4个周期。比较两组患者疗效、不良反应发生率。比较两组治疗前、治疗4个周期后的肺功能、T细胞亚群和生存质量。结果：治疗4个周期后，研究组的临床总有效率为58.62%（34/58），高于对照组的39.66%（23/58）（P<0.05）。治疗4个周期后，两组患者CD4+、CD3+、CD4+/CD8+水平均下降，但研究组高于对照组（P<0.05），CD8+水平均升高，但研究组低于对照组（P<0.05）。两组治疗4个周期后躯体功能、认知功能、角色功能、社会功能以及情绪功能评分以及第1 s用力呼气容积（FEV1）、用力肺活量（FVC）、呼气峰流速值（PEF）均升高，且研究组高于对照组（P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。结论：扶正解毒方联合恩度治疗晚期NSCLC患者，疗效较好，可减轻免疫抑制，提高生存质量及肺功能，且不增加不良反应发生率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Fuzheng Jiedu formula combined with endu on lung function, T cell subsets and quality of life in patients with advanced non-small cell lung cancer (NSCLC). Methods: 116 patients with advanced NSCLC who were admitted to our hospital from March 2016 to October 2018 were randomly selected, patients were divided into two groups: control group (n=58, endu combined chemotherapy) and study group (n=58, combined with Fuzheng Jiedu formula on the basis of control group). The chemotherapy cycle was 21 days, with a total of 4 cycles. The curative effect and the incidence of adverse reactions were compared between the two groups. Lung function, T cell subsets and quality of life of the two groups before and 4 cycles after treatment were compared. Results: 4 cycles after treatment, the total clinical effective rate of the study group was 58.62% (34/58), which was higher than that of the control group 39.66% (23/58)(P<0.05). 4 cycles after treatment, the levels of CD4+++++1), forced vital capacity(FVC), peak expiratory flow rate (PEF) were all increased in the two groups at 4 cycles after treatment, and those in the study group were higher than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: The Fuzheng Jiedu formula combined with endu has a good effect on patients with advanced NSCLC It can reduce the immunosuppression, improve the quality of life and lung function, and does not increase the incidence of adverse reactions. |
|
View Full Text
View/Add Comment Download reader |
| Close |
